February 01, 2019
3 min read

Statin therapy reduces CV risks across age groups, including elderly

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The use of statin therapy led to notable declines in major vascular events across several age groups, including patients older than 75 years, according to findings published in The Lancet.

Researchers performed a meta-analysis comprised of participant-level data from 22 trials with 134,537 participants and detailed summary data from one trial (n = 12,705) of statin therapy vs. a control group, plus individual participant data from five trials of more intensive vs. less intensive statin therapy (n = 39,612).

Effect on major vascular events

Jordan Fulcher, BSc, MBBS, of the Cholesterol Treatment Trialists’ Collaboration at the University of Sydney NHMRC Clinical Trials Centre, and colleagues estimated effects on major vascular events, cause-specific mortality and cancer incidence as the rate ratio per 1 mmol/L reduction in LDL, with participants divided into six age groups (55 years and younger, 56 to 60 years, 61 to 65 years, 66 to 70 years, 71 to 75 years and older than 75 years).

From the 28 randomized trials, researchers identified 14,483 participants (8%) older than 75 years (median follow-up, 4.9 years).

Fulcher and colleagues identified a 21% proportional reduction in major vascular events per 1 mmol/L reduction in LDL (RR = 0.79; 95% CI, 0.77-0.81) with statin therapy or a more intensive statin regimen. Statin or more intensive therapy yielded a 24% proportional reduction in major coronary events per 1 mmol/L lower LDL (RR = 0.76; 95% CI, 0.73-0.79).

Researchers also identified a 25% proportional reduction in the risk for coronary revascularization procedures with statin therapy or a more intensive statin regimen per 1 mmol/L lower LDL (RR = 0.76; 95% CI, 0.73-0.78), which didn’t differ significantly across age groups (P for trend = .6).

Statin therapy was associated with a 16% proportional risk for stroke of any type (RR = 0.84; 95% CI, 0.8-0.89) and did not differ significantly across any age group (P for trend = .7).

Excluding four trials enrolling only patients with HF or undergoing hemodialysis, smaller proportional trend risk reductions with increasing age persisted for major coronary events (P for trend = .01). The proportional reduction in major vascular events in participants not known to have vascular disease was smaller among older patients compared with younger (P for trend = .05), researchers wrote.

Fulcher and colleagues identified there was a 12% proportional reduction in vascular mortality for 1 mmol/L reduction in LDL (RR = 0.88; 95% CI, 0.85-0.91), with a trend towards smaller reductions with older age (P for trend = .004), but the trend did not persist when trials of patients with HF or on dialysis were excluded (P for trend = .2).


Researchers added that statin therapy had no effect at any age on nonvascular mortality, cancer death or cancer incidence.

“Statin therapy produces significant reductions in major vascular events, irrespective of age,” Fulcher and colleagues wrote. “There is less definitive direct evidence of benefit in the primary prevention setting among patients older than 75 years who do not already have evidence of occlusive vascular disease.”

Weighing risks and benefits

In a related editorial, Bernard M. Y. Cheung, PhD, MA, MB BChir, MRCP, FRCP, FHKCP, FHKAM, and Karen S.L. Lam, MD, MBBS, FHKCP, FHKAM, FRCP, both from the department of medicine at Queen Mary Hospital at the University of Hong Kong, wrote: “When statins are used in people with low cardiovascular risk, the risks and benefits need to be weighed against each other. Statins have been associated with a slight increase in incidence of muscle pain, diabetes and hemorrhagic stroke, but their benefits in prevention of major vascular events are shown to be much greater. The present meta-analysis that includes people older than standard trial populations echoes this conclusion.” – by Earl Holland Jr.

Disclosures: Fulcher reports he receives personal fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Pfizer and Sanofi. Cheung reports he receives personal fees from Amgen, Pfizer and Roche. Lam reports she receives personal fees from AstraZeneca and Merck Sharpe and Dohme. Please see the study for all other authors’ relevant financial disclosures.